Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete